<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25239521</article-id><article-id pub-id-type="pmc">4179224</article-id><article-id pub-id-type="publisher-id">4863</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-684</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>A randomized phase II clinical trial of
nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line
therapy in locally advanced or metastatic squamous cell carcinoma of
lung</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jin-Ji</given-names></name><address><email>yangjinji2003@163.com</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Cheng</given-names></name><address><email>cheng671@sina.com</email></address><xref ref-type="aff" rid="Aff17"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Gong-Yan</given-names></name><address><email>chengongyan@medmail.com.cn</email></address><xref ref-type="aff" rid="Aff18"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Yong</given-names></name><address><email>yong_song1963101@sina.com</email></address><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Ying</given-names></name><address><email>chengying@csco.org.cn</email></address><xref ref-type="aff" rid="Aff20"/></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Hong-Hong</given-names></name><address><email>yanhonghong385@126.com</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Qing</given-names></name><address><email>gzzhouqing@126.com</email></address><xref ref-type="aff" rid="Aff16"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Yi-Long</given-names></name><address><email>syylwu@live.cn</email></address><xref ref-type="aff" rid="Aff16"/></contrib><aff id="Aff16"><label/>Guangdong Lung Cancer Institute, Guangdong General Hospital &#x00026; Guangdong Academy of Medical
Sciences, 106 Zhong Shan Dong Er road, Guangzhou, China </aff><aff id="Aff17"><label/>Fujian Province Cancer Hospital, 91 Fu Ma road, Fuzhou, China </aff><aff id="Aff18"><label/>Heilongjiang Province Cancer Hospital, 150 Ha Ping road, Harbin, China </aff><aff id="Aff19"><label/>Nanjing General Hospital, 305 Zhong Shan Dong road, Nanjing, China </aff><aff id="Aff20"><label/>Jilin Province Cancer Hospital, 1018 Hu Guang road, Changchun, China </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>684</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Yang et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is
an Open Access article distributed under the terms of the Creative Commons
Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0">http://creativecommons.org/publicdomain/zero/1.0</ext-link>) applies to the data made available in this article, unless
otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Recent advances have shown that histology and genetic biomarkers are important
in patient selection, which have led to significantly better outcomes for lung
cancer patients. However, most new treatments only apply to adenocarcinoma or
non-squamous, and in squamous carcinoma there is little breakthrough. In a phase
III trial nab-paclitaxel plus carboplatin showed superior response rate over
paclitaxel and carboplatin. In subgroup analysis the squamous histology appeared
to be a predictive factor to nab-paclitaxel treatment.</p></sec><sec><title>Methods/Design</title><p>This is an open-label, randomized, active controlled phase II trial. A total
of 120 untreated advanced squamous lung cancer patients are randomized at a 1:1
ratio to receive nab-paclitaxel (135&#x000a0;mg/m<sup>2</sup>, d1, 8, q3w)
plus carboplatin (AUC 5, d1, q3w) or gemcitabine
(1,250&#x000a0;mg/m<sup>2</sup>, d1, 8, q3w) and carboplatin (AUC 5, d1,
q3w). The primary endpoint is objective response rate and the second endpoints are
progression free survival, overall survival, safety and biomarkers associated with
nab-paclitaxel. The treatment will continue up to six cycles or intolerable
toxicity.</p></sec><sec><title>Discussion</title><p>This ongoing trial will be the first prospective randomized trial to explore
the efficacy of nab-paclitaxel as the first-line treatment specifically in
squamous carcinoma of lung.</p></sec><sec><title>Study number</title><p>CTONG1002</p></sec><sec><title>Trial Registration</title><p>Clinicaltrials.gov reference: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov/ct2/results?term=NCT01236716&#x00026;Search=Search">NCT01236716</ext-link></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nab-paclitaxel</kwd><kwd>Carboplatin</kwd><kwd>Gemcitabine</kwd><kwd>Squamous</kwd><kwd>Carcinoma</kwd><kwd>Lung</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>For both men and women, lung cancer is the leading cause of death and non-small
cell lung cancer (NSCLC) represents more than 80% of all lung cancer cases
[<xref ref-type="bibr" rid="CR1">1</xref>]. Compared with best supportive
care, platinum-based doublet chemotherapy not only prolongs the survival, but also
improves symptom control and the quality of life. It has been the standard of care
for advanced NSCLC [<xref ref-type="bibr" rid="CR2">2</xref>]. Available data
suggest that different platinum/third generation chemotherapy agent combinations
have similar efficacy in the first line setting [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Traditionally, the choice of chemotherapy is based on performance status, age,
etc, and histology has not influenced the treatment options. Recent years,
personalized treatment has developed rapidly with the emerging of new chemotherapy
agents and targeted therapies. Pemetrexed has favorable efficacy and safety profiles
in non-squamous NSCLC but not in squamous population [<xref ref-type="bibr" rid="CR4">4</xref>]. The benefit of bevacizumab is also limited to the non-squamous
subtypes [<xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, most targeted
drugs need molecular markers to distinguish patients who would likely to gain
survival advantage from treatment, such as epidermal growth factor receptor (EGFR)
mutation for EGFR tyrosine kinase inhibitors (TKIs) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], EGFR
amplification for cetuximab [<xref ref-type="bibr" rid="CR8">8</xref>] and
anaplastic lymphoma kinase (ALK) fusion-positive for ALK inhibitor crizotinib
[<xref ref-type="bibr" rid="CR9">9</xref>]. Molecular-targeted drugs have the
advantages of prominent therapeutic efficacy and moderate adverse reactions,
prolonging patients&#x02019; survival time and improving the quality of life at the same
time. EGFR-TKIs such as erlotinib and gefitinib have been recommended as the first
-line treatment in EGFR mutation patients by clinical practice guidelines
[<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>Despite all the progress in adenocarcinoma and biomarker positive patients, the
treatment breakthroughs for squamous histology are few. Although the EGFR mutated
squamous lung cancer patients can be treated with EGFR-TKIs as well, the mutation
rate in this population is much lower than that in the non-squamous subtypes (around
10% in Caucasian adenocarcinoma patients, 30% in Asian adenocarcinoma patients, but
only around 3% in squamous patients [<xref ref-type="bibr" rid="CR10">10</xref>]). Thus major part of squamous patients remains on platinum-based
doublet with an average objective response rate (ORR) around 20% and overall
survival (OS) no longer than 12&#x000a0;months.</p><p>Nab-paclitaxel (Abraxane) is a nano-technology developed albumin bound
paclitaxel. With the natural affinity of albumin to tumor cells, it enables
paclitaxel to be concentrated in cancer lesion to exert bigger anti-neoplastic
effect. In a phase III trial of Abraxane plus carboplatin versus solvent-based
paclitaxel [<xref ref-type="bibr" rid="CR11">11</xref>], Abraxane arm shows
significantly higher ORR than the solvent-based paclitaxel arm (33% vs 25%,
p&#x02009;=&#x02009;0.005) and equivalent progression free survival (PFS) and OS. The ORR benefit is
especially bigger in squamous subtype (41% vs 24%, p&#x02009;&#x0003c;&#x02009;0.001) and the OS
beneficial trend is bigger in this group too.</p><p>With these promising findings of subtype analysis in the phase III trial, this
trial is designed to prospectively explore the efficacy of Abraxane specifically in
the squamous population by a head to head comparison to current standard of
care.</p></sec><sec id="Sec2"><title>Methods/Design</title><p>This study is a multicenter, randomized, active controlled, open label phase II
clinical trial. The objective is to study the efficacy and safety of nab-paclitaxel
and carboplatin compared with gemcitabine and carboplatin as first-line therapy in
advanced squamous cell carcinoma of lung. All patients in this study have locally
advanced or metastatic squamous cell carcinoma of lung which has been histologically
confirmed. The inclusion and exclusion criteria are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. This study was approved by the ethics committees of
Guangdong General Hospital, Fujian Province Cancer Hospital, Heilongjiang Province
Cancer Hospital, Nanjing General Hospital and Jilin Province Cancer Hospital
respectively.Recruitment for this study is currently ongoing in 5 sites in China.
Written informed consent must be provided by all patients before any trial-related
procedures are carried out. 120 patients are randomly assigned to treatment group A:
receiving nab-paclitaxel 135&#x000a0;mg/m<sup>2</sup>, d1, 8 and carboplatin
AUC 5, d1 every three weeks; or group B: receiving gemcitabine
1,250&#x000a0;mg/m<sup>2</sup>, plus carboplatin AUC 5, d1 every three
weeks. Both group A and B receive up to six cycles of chemotherapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Inclusion and exclusion criteria</bold>
</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="18">
<bold>Inclusion criteria</bold>
</td><td>&#x02022; Previously untreated, histologically documented stage IIIB
to stage IV or stage IIIA that is not amenable to regional therapy
(7<sup>th</sup> Edition of TNM Staging Criteria)
squamous cell carcinoma of lung. Previously untreated, histologically
documented squamous cell carcinoma of lung with stage IV or locally
advanced disease that is not amenable to radical regional therapy
(7<sup>th</sup> Edition of TNM Staging
Criteria).</td></tr><tr><td>&#x02022; At least one measurable tumor lesion as defined by RECIST
criteria.</td></tr><tr><td>&#x02022; 18 to 85 years of age.</td></tr><tr><td>&#x02022; ECOG performance status 0-1.</td></tr><tr><td>&#x02022; Patients have no previously malignant tumors or history
except cured cervical carcinoma in situ, basal cell carcinoma or
superficial bladder cancer (T<sub>a</sub>,
T<sub>is</sub> or T<sub>1</sub>).</td></tr><tr><td>&#x02022; Patients should not have been treated with chemotherapy such
as gemcitabine, platinum and taxane. But patients who have received
chemotherapy for neoadjuvant or adjuvant treatment at least 12 months
before the study treatment are eligible.</td></tr><tr><td>&#x02022; Patients&#x02019; blood test must meet the following
requirements:</td></tr><tr><td>
o ANC &#x02265; 1.5 x
10<sup>9</sup>/L</td></tr><tr><td>
o Platelets &#x02265; 100 x
10<sup>9</sup>/L</td></tr><tr><td>
o Hb &#x02265; 90 g/L (9
g/dL)</td></tr><tr><td>&#x02022; Patients&#x02019; clinical biochemistry examination must meet the
following requirements:</td></tr><tr><td>
o ALT and AST &#x02264; 2.5
x upper limit of normal (ULN) without liver metastasis, ALT and AST &#x02264; 5
x ULN with liver metastases</td></tr><tr><td>
o Serum creatinine &#x02264;
1.5 x ULN</td></tr><tr><td>
o Total bilirubin &#x02264;
1.5 x ULN</td></tr><tr><td>&#x02022; Urine pregnancy test is negative for women, within 14 days
before study treatment.</td></tr><tr><td>&#x02022; Estimated life expectancy of at least 3 months.</td></tr><tr><td>&#x02022; Patients will comply with the clinical trial
protocol.</td></tr><tr><td>&#x02022; Patients voluntarily participate in clinical trial and the
informed consent must be signed.</td></tr><tr><td rowspan="9">
<bold>Exclusion criteria</bold>
</td><td>&#x02022; Patients who are currently undergoing other anti-tumor
therapies.</td></tr><tr><td>&#x02022; Patients who were enrolled into any other clinical trial
within 4 weeks of study entry.</td></tr><tr><td>&#x02022; Any clinical laboratory findings give reasonable suspicion
of a disease or condition that contraindicates the use of any study
medication or render the subject at high risk from
treatment.</td></tr><tr><td>&#x02022; Primary brain tumor or central nervous system metastatic
tumor.</td></tr><tr><td>&#x02022; Serious mental disorder.</td></tr><tr><td>&#x02022; Serious dysgnosia or cognitive dysfunction.</td></tr><tr><td>&#x02022; Other serious comorbidities.</td></tr><tr><td>&#x02022; Alcohol or drug dependence.</td></tr><tr><td>&#x02022; Previously allergic to drugs used in the study.</td></tr><tr><td/><td>&#x02022; Patients who are deemed unsuitable to participate in the
study</td></tr></tbody></table></table-wrap></p><sec id="Sec3"><title>Study objectives</title><p>The primary objective of this study is to compare the ORR of Abraxane plus
carboplatin to gemcitabine plus carboplatin. Secondary objectives include PFS, OS,
safety and biomarker parameters. Exploratory endpoints include expression of
secreted protein acid rich in cysteine (SPARC) and caveolin-1 in NSCLC tissue and
their predictive value in PFS and OS. Tumor samples will be collected from all
randomized patients and tested in the central lab of Guangdong Lung Cancer
Institute, Guangdong Academy of Medical Sciences.</p></sec><sec id="Sec4"><title>Statistics</title><p>The sample size calculation assumes that in advanced squamous lung cancer,
Abraxane&#x02009;+&#x02009;carboplatin has an ORR of 40% [<xref ref-type="bibr" rid="CR11">11</xref>] while gemcitabine&#x02009;+&#x02009;carboplatin has an ORR of 19%
[<xref ref-type="bibr" rid="CR3">3</xref>]. With inequality test using
ratios of two independent proportions, the sample size is 120 patients in total,
which will be randomly assigned at a 1:1 ratio between two treatment arms (60 in
each). This sample size will provide 80% power with two-sided type I error of 0.05
to reject the primary efficacy null hypothesis that
Abraxane&#x02009;+&#x02009;carboplatin/gemcitabine&#x02009;+&#x02009;carboplatin hazard ratio for ORR is equal to
1.0.</p><p>The primary objective will be analyzed by chi-square test. Secondary endpoints
of PFS and OS will be evaluated by Kaplan-Meier method with a 95% confidence
interval. The log-rank method will be used to compare the difference between the
survival curves of two arms. Multifactorial Cox regression analysis will be used
to determine the prognostic factors of the survivals including PFS and OS.</p></sec><sec id="Sec5"><title>Ethical considerations</title><p>Prior to initiation of the study, each of the participating sites must obtain
local or central ethics committee approval from the appropriate body. All research
will conform to the Declaration of Helsinki, as well as local legal and ethical
requirements.</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p>Previous researches have shown comparable efficacy and good safety profile of
Abraxane-based chemotherapy in the first-line treatment of advanced NSCLC, compared
to other standard platinum-based doublets. In a phase III trial, the ORR of Abraxane
plus carboplatin is significantly higher than solvent-based paclitaxel and the
survival time is equivalent in two groups [<xref ref-type="bibr" rid="CR11">11</xref>]. The most common adverse events of interest in Abraxane arm are
hematological toxicity and neuropathy. The incidence of Grade 3-4 thrombocytopenia
and anemia are higher in Abraxane group than solvent-based paclitaxel arm, while the
incidence of neutropenia is higher in solvent-based paclitaxel arm. Generally, the
majority of hematological toxicities in both arms are Grade 1-2 and manageable.
Grade 3-4 sensory neuropathy occurred more frequently in solvent-based paclitaxel
arm than Abraxane arm (12% vs 3%) and the median time to improvement of Grade 3-4
neuropathy to Grade 1 is much less for Abraxane arm than solvent-based paclitaxel
arm (38&#x000a0;days vs 104&#x000a0;days). Thus Abraxane seems an optimal choice of third generation
chemotherapy agents to be combined with platinum as the standard treatment due to
its high activity and favorable safety profile.</p><p>Moreover, retrospective subgroup analyses showed that in squamous histology
group, there were more significant ORR benefit and OS improvement trend. Squamous
cell carcinoma consists approximately 30% of all NSCLC but new treatment options are
few. There is huge unmet medical need to increase the prognosis of this patient
population. Abraxane has the active agent of paclitaxel, which is an approved agent
for treatment of squamous cell lung cancer, as well as the albumin-bound property
which increases the drug distribution and concentration to a new level. Furthermore,
studies have showed that SPARC is an albumin-bound protein that is rich in tumor
matrix and may plays an important role in absorbing Abraxane into the tumor site
[<xref ref-type="bibr" rid="CR12">12</xref>]. SPARC may serve as a predictive
or prognostic biomarker of Abraxane-based therapy. Thus Abraxane has the potential
to be the optimal treatment choice in squamous carcinoma of lung to achieve better
response and survival.</p><p>This trial will be the first study to prospectively compare Abraxane-based
regimen with a currently standard treatment for squamous histology patients. A total
of 120 patients will be randomized at a 1:1 ratio to receive Abraxane
135&#x000a0;mg/m<sup>2</sup>, d1,8 plus carboplatin AUC 5, d1, or
gemcitabine 1,250&#x000a0;mg/m<sup>2</sup> plus carboplatin AUC 5, d1, both
in a cycle of three weeks and up to six cycles. The choice of Abraxane dosage and
schedule is based on previous researches and the phase III trial result. Weekly
Abraxane has been proved to have better efficacy and safety than every three week
schedule [<xref ref-type="bibr" rid="CR13">13</xref>]. Compared to
100&#x000a0;mg/m<sup>2</sup> d1, 8, 15 in a four-week&#x000a0;cycle in the phase
III trial, we implement a modified 135&#x000a0;mg/m<sup>2</sup> , d1, 8 in a
three-week&#x000a0;cycle schedule to ensure a similar dose intensity but more timely
treatment break in order to further reduce toxicity.</p><p>This study, together with findings from other phase I/II/III studies of Abraxane
in NSCLC, will provide valuable insight to the role of Abraxane in the optimal
treatment choice for squamous carcinoma of lung.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>This study received research grant from Celgene Corporation.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>All authors have been involved in critically revising the drafts of the
manuscript and read and approved the final manuscript. JJY was involved in
manuscript drafting. All authors have been involved in the development of the study
design. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This trial is supported by Celgene Corporation. The authors take full
responsibility for the content of this publication.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Office for Cancer Prevention and Control &#x00026;
National Central Cancer Registry, Disease Prevention and Control Bureau,
Ministry of Health</collab></person-group><source>Chinese Cancer Registry Annual Report 2010: Cancer Incidence and
Mortality in Chinese Cancer Registration Areas in 2007</source><year>2011</year><publisher-loc>No. 27 Taiping Road Haidian District, Beijing, China (Postcode:
100850)</publisher-loc><publisher-name>Military Medical Science Publishing House</publisher-name></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other"><bold>National Comprehensive Cancer Network (NCCN) NCCN Clinical
Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Fort Washington,
PA: NCCN; 2011. Ver. 2.2012</bold> [<ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link>]</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Harrington</surname><given-names>D</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Sandler</surname><given-names>A</given-names></name><name><surname>Krook</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name><collab>Eastern Cooperative Oncology
Group</collab></person-group><article-title>Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011954</pub-id><pub-id pub-id-type="pmid">11784875</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>GV</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>von Pawel</surname><given-names>J</given-names></name><name><surname>Biesma</surname><given-names>B</given-names></name><name><surname>Vansteenkiste</surname><given-names>J</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><name><surname>Serwatowski</surname><given-names>P</given-names></name><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Digumarti</surname><given-names>R</given-names></name><name><surname>Zukin</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Mellemgaard</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Rolski</surname><given-names>J</given-names></name><name><surname>Goksel</surname><given-names>T</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><name><surname>Simms</surname><given-names>L</given-names></name><name><surname>Sugarman</surname><given-names>KP</given-names></name><name><surname>Gandara</surname><given-names>D</given-names></name></person-group><article-title>Phase III study comparing cisplatin plus gemcitabine
with cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3543</fpage><lpage>3551</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.0375</pub-id><pub-id pub-id-type="pmid">18506025</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Perry</surname><given-names>MC</given-names></name><name><surname>Brahmer</surname><given-names>J</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Dowlati</surname><given-names>A</given-names></name><name><surname>Lilenbaum</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name></person-group><article-title>Paclitaxel-carboplatin alone or with bevacizumab for
non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>2542</fpage><lpage>2550</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa061884</pub-id><pub-id pub-id-type="pmid">17167137</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>TS</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Chu</surname><given-names>DT</given-names></name><name><surname>Saijo</surname><given-names>N</given-names></name><name><surname>Sunpaweravong</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Margono</surname><given-names>B</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Nishiwaki</surname><given-names>Y</given-names></name><name><surname>Ohe</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Chewaskulyong</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Duffield</surname><given-names>EL</given-names></name><name><surname>Watkins</surname><given-names>CL</given-names></name><name><surname>Armour</surname><given-names>AA</given-names></name><name><surname>Fukuoka</surname><given-names>M</given-names></name></person-group><article-title>Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>947</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810699</pub-id><pub-id pub-id-type="pmid">19692680</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Carcereny</surname><given-names>E</given-names></name><name><surname>Gervais</surname><given-names>R</given-names></name><name><surname>Vergnenegre</surname><given-names>A</given-names></name><name><surname>Massuti</surname><given-names>B</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Palmero</surname><given-names>R</given-names></name><name><surname>Garcia-Gomez</surname><given-names>R</given-names></name><name><surname>Pallares</surname><given-names>C</given-names></name><name><surname>Sanchez</surname><given-names>JM</given-names></name><name><surname>Porta</surname><given-names>R</given-names></name><name><surname>Cobo</surname><given-names>M</given-names></name><name><surname>Garrido</surname><given-names>P</given-names></name><name><surname>Longo</surname><given-names>F</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Insa</surname><given-names>A</given-names></name><name><surname>De Marinis</surname><given-names>F</given-names></name><name><surname>Corre</surname><given-names>R</given-names></name><name><surname>Bover</surname><given-names>I</given-names></name><name><surname>Illiano</surname><given-names>A</given-names></name><name><surname>Dansin</surname><given-names>E</given-names></name><name><surname>de Castro</surname><given-names>J</given-names></name><name><surname>Milella</surname><given-names>M</given-names></name><name><surname>Reguart</surname><given-names>N</given-names></name><name><surname>Altavilla</surname><given-names>G</given-names></name><name><surname>Jimenez</surname><given-names>U</given-names></name><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>MA</given-names></name><name><surname>Terrasa</surname><given-names>J</given-names></name><name><surname>Mu&#x000f1;oz-Langa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Erlotinib versus standard chemotherapy as first-line
treatment for European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicenter, open-label, ransomised phase
3 trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>3</issue><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70393-X</pub-id><pub-id pub-id-type="pmid">22285168</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirker</surname><given-names>R</given-names></name><name><surname>Pereira</surname><given-names>JR</given-names></name><name><surname>Szczesna</surname><given-names>A</given-names></name><name><surname>von Pawel</surname><given-names>J</given-names></name><name><surname>Krzakowski</surname><given-names>M</given-names></name><name><surname>Ramlau</surname><given-names>R</given-names></name><name><surname>Vynnychenko</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>CT</given-names></name><name><surname>Ganul</surname><given-names>V</given-names></name><name><surname>Roh</surname><given-names>JK</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>O'Byrne</surname><given-names>K</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><name><surname>Eberhardt</surname><given-names>W</given-names></name><name><surname>Goddemeier</surname><given-names>T</given-names></name><name><surname>Emig</surname><given-names>M</given-names></name><name><surname>Gatzemeier</surname><given-names>U</given-names></name><collab>FLEX Study Team</collab></person-group><article-title>Cetuximab plus chemotherapy in patients with advanced
non-small-cell lung cancer (FLEX): an open-label randomized phase III
trial</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1525</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60569-9</pub-id><pub-id pub-id-type="pmid">19410716</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><name><surname>Camdge</surname><given-names>DR</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Solomon</surname><given-names>B</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Ou</surname><given-names>SH</given-names></name><name><surname>Dezube</surname><given-names>BJ</given-names></name><name><surname>J&#x000e4;nne</surname><given-names>PA</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Varella-Garcia</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Fidias</surname><given-names>P</given-names></name><name><surname>Stubbs</surname><given-names>H</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>GC</given-names></name><name><surname>Shreeve</surname><given-names>SM</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Wilner</surname><given-names>K</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Anaplastic lymphoma kinase inhibition in
non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>1693</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1006448</pub-id><pub-id pub-id-type="pmid">20979469</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>SA</given-names></name><name><surname>Bharma</surname><given-names>G</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Kok</surname><given-names>C</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><article-title>The catalogue of somatic mutations in cancer
(COSMICS)</article-title><source>Curr Protoc Hum Genet</source><year>2008</year><volume>4</volume><fpage>1</fpage><lpage>32</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socinski</surname><given-names>MA</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Karaseva</surname><given-names>NA</given-names></name><name><surname>Makhson</surname><given-names>AM</given-names></name><name><surname>Vynnychenko</surname><given-names>I</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Hon</surname><given-names>JK</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>Bhar</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Iglesias</surname><given-names>JL</given-names></name><name><surname>Renschler</surname><given-names>MF</given-names></name></person-group><article-title>Weekly nab-paclitaxel in combination with carboplatin
versus solvent-based paclitaxel plus carboplatin as first-line therapy in
patients with advanced non-small-cell lung cancer: final results of a phase III
trial</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>2055</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.5848</pub-id><pub-id pub-id-type="pmid">22547591</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koukourakis</surname><given-names>MI</given-names></name><name><surname>Giatromanolaki</surname><given-names>A</given-names></name><name><surname>Brekken</surname><given-names>R</given-names></name><name><surname>Sivridis</surname><given-names>E</given-names></name><name><surname>Gatter</surname><given-names>KC</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Sage</surname><given-names>EH</given-names></name></person-group><article-title>Enhanced expression of SPARC/osteonectin in the
tumor-associated stroma of non-small cell lung cancer is correlated with markers
of hyposia/acidity and with poor prognosis of patients</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>5376</fpage><lpage>5380</lpage><pub-id pub-id-type="pmid">14500371</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socinski</surname><given-names>MA</given-names></name><name><surname>Manikhas</surname><given-names>GM</given-names></name><name><surname>Stroyakovsky</surname><given-names>DL</given-names></name><name><surname>Makhson</surname><given-names>AN</given-names></name><name><surname>Cheporov</surname><given-names>SV</given-names></name><name><surname>Orlov</surname><given-names>SV</given-names></name><name><surname>Yablonsky</surname><given-names>PK</given-names></name><name><surname>Bhar</surname><given-names>P</given-names></name><name><surname>Iglesias</surname><given-names>J</given-names></name></person-group><article-title>A dose finding study of weekly and every-3-week
nab-paclitaxel followed by carboplatin as first-line therapy in patients with
advanced non-small cell lung cancer</article-title><source>J Thorac Oncol</source><year>2010</year><volume>5</volume><fpage>852</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181d5e39e</pub-id><pub-id pub-id-type="pmid">20521351</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR14"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/684/prepub">http://www.biomedcentral.com/1471-2407/14/684/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>